Pharmacokinetic evaluation of pramipexole

Expert Opinion on Drug Metabolism and Toxicology

Volumn 7, Issue 10, 2011, Pages 1307-1314

  Antonini, Angelo ^a   Calandrella, Daniela ^b  

^a IRCCS SAN CAMILLO HOSPITAL   (Italy)

^b Clinic San Pio X   (Italy)

Author keywords

Continuous drug delivery; Extended release; Immediate release; Pharmacokinetic; Pramipexole

Indexed keywords

PRAMIPEXOLE;

BINDING AFFINITY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG FORMULATION; DRUG METABOLISM; DRUG RELEASE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TRANSFORMATION; HUMAN; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PARKINSON DISEASE; REVIEW; STEADY STATE;

BENZOTHIAZOLES; DOPAMINE AGONISTS; DRUG DELIVERY SYSTEMS; DRUG EVALUATION; DRUG TOXICITY; ENDPOINT DETERMINATION; HEART VALVE DISEASES; HUMANS; LEVODOPA; PARKINSON DISEASE; PHARMACOGENETICS; RECEPTORS, DOPAMINE; RESTLESS LEGS SYNDROME;

EID: 80053032491     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2011.614232     Document Type: Review

References (41)

1. Olanow CW, Stern MB, Sethi K. The scientific and clinical basis for the treatment of Parkinson disease (2009). Neurology 2009;72(21 Suppl 4):S1-136
2. Horstink M, Tolosa E, Bonuccelli U, et al. Review of the therapeutic management of Parkinsons disease. Report of a joint task force of the European Federation of Neurological Societies and the Movement Disorder Society-European Section. Part I: early (uncomplicated) Parkinsons disease. Eur J Neurol 2006;13(11):1170-85
3. Piercey MF. Pharmacology of pramipexole, a dopamine D3-preferring agonist useful in treating Parkinsons disease. Clin Neuropharmacol 1998;21(3):141-51 (Pubitemid 28248773)
4. Mierau J, Schneider FJ, Ensinger HA, et al. Pramipexole binding and activation of cloned and expressed dopamine D2, D3 and D4 receptors. Eur J Pharmacol 1995;290(1):29-36
5. Maj J, Rogoi Z, Margas W, et al. The effect of repeated treatment with pramipexole on the central dopamine D3 system. J Neural Transm 2000;107(12):1369-79 (Pubitemid 32049933)
6. Antonini A, Poewe W. Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinsons disease. Lancet Neurol 2007;6(9):826-9 (Pubitemid 47243713)
7. Wright CE, Sisson TL, Ichhpurani AK, Peters GR. Steady-state pharmacokinetic properties of pramipexole in healthy volunteers. J Clin Pharmacol 1997;37(6):520-5 (Pubitemid 27265653)
8. Wright CE, Grasela TH, Philips L. The population pharmacokinetics of pramipexole in Parkinsons disease patients. Clin Pharmacol Ther 1997;61:182 (Pubitemid 127791431)
9. Wynalda MA, Wienkers LC. Assessment of potential interactions between dopamine receptor agonists and various human cytochrome P450 enzymes using a simple in vitro inhibition screen. Drug Metab Dispos 1997;25:1211-14 (Pubitemid 27446593)
10. Hubble JP. Pre-clinical studies of pramipexole: clinical relevance. Eur J Neurol 2000;7(Suppl 1):15-20 (Pubitemid 32260557)
11. Wu MJ, Ing TS, Soung LS, et al. Amantadine hydrochloride pharmacokinetics in patients with impaired renal function. Clin Nephrol 1982;17:19-23 (Pubitemid 12212628)
12. Ishiguro N, Saito A, Yokoyama K, et al. Transport of the dopamine D2 agonist pramipexole by rat organic cation transporters OCT1 and OCT2 in kidney. Drug Metab Dispos 2005;33(4):495-9 (Pubitemid 40393191)
13. Jenner P, Konen-Bergmann M, Schepers C, Haertter S. Pharmacokinetics of a once-daily extended-release formulation of pramipexole in healthy male volunteers: three studies. Clin Ther 2009;31(11):2698-711
14. Eisenreich W, Sommer B, Hartter S, Jost WH. Pramipexole extended-release: a novel treatment option in Parkinsons disease. Parkinsons Dis 2010;2010:612619
15. Soto E, Haertter S, Koenen-Bergmann M, et al. Population in vitro-in vivo correlation model for pramipexole slow-release oral formulations. Pharm Res 2010;27(2):340-9
16. Ferger B, Buck K, Shimasaki M, et al. Continuous dopaminergic stimulation by pramipexole is effective to treat early morning akinesia in animal models of Parkinsons disease: a pharmacokinetic-pharmacodynamic study using in vivo microdialysis in rats. Synapse 2010;64(7):533-41
17. Triggs EJ, Charles BG, Contin M, et al. Population pharmacokinetics and pharmacodynamics of oral levodopa in parkinsonian patients. Eur J Clin Pharmacol 1996;51(1):59-67 (Pubitemid 26300935)
18. Kompoliti K, Adler CH, Raman R, et al. Gender and pramipexole effects on levodopa pharmacokinetics and pharmacodynamics. Neurology 2002;58(9):1418-22 (Pubitemid 34507176)
19. Nanko S, Hattori M, Ueki A, Ikeda K. Dopamine D3 and D4 receptor gene polymorphisms and Parkinsons disease. Lancet 1993;342(8865):250 (Pubitemid 23214669)
20. Zappia M, Annesi G, Quattrone A. Association study of dopamine D2, D3 receptor gene polymorphisms with motor fluctuations in PD. Neurology 2002;58(5):837
21. Paus S, Grunewald A, Klein C, et al. The DRD2 TaqIA polymorphism and demand of dopaminergic medication in Parkinsons disease. Mov Disord 2008;23(4):599-602
22. Suzuki A, Mihara K, Kondo T, et al. The relationship between dopamine D2 receptor polymorphism at the Taq1 A locus and therapeutic response to nemonapride, a selective dopamine antagonist, in schizophrenic patients. Pharmacogenetics 2000;10:335-41 (Pubitemid 30345181)
23. Paus S, Gadow F, Knapp M, et al. Motor complications in patients form the German competence network on Parkinsons disease and the DRD3 Ser9Gly polymorphism. Mov Disord 2009;24(7):1080-4
24. Arbouw ME, Movig KL, Egberts TC, et al. Clinical and pharmacogenetic determinants for the discontinuation of non-ergoline dopamine agonists in Parkinsons disease. Eur J Clin Pharmacol 2009;65(12):1245-51
25. Liu YZ, Tang BS, Yan XX, et al. Association of the DRD2 and DRD3 polymorphisms with response to pramipexole in Parkinsons disease patients. Eur J Clin Pharmacol 2009;65(7):679-83
26. Diao L, Shu Y, Polli JE. Uptake of pramipexole by human organic cation transporters. Mol Pharm 2010;7(4):1342-7
27. Patterson TA, Li M, Hotchkiss CE, et al. Toxicity assessment of pramipexole in juvenile rhesus monkeys. Toxicology 2010;276(3):164-71
28. Antonini A, Tolosa E, Mizuno Y, et al. A reassessment of risks and benefits of dopamine agonists in Parkinsons disease. Lancet Neurol 2009;8(10):929-37
29. Grosset D, Antonini A, Canesi M, et al. Adherence to antiparkinson medication in a multicenter European study. Mov Disord 2009;24(6):826-32
30. Antonini A, Barone P, Ceravolo R, et al. Role of pramipexole in the management of Parkinsons disease. CNS Drugs 2010;24(10):829-41
31. Poewe W, Rascol O, Barone P, et al. Extended-release pramipexole in early Parkinsons disease: a 33-week randomized controlled trial. Neurology 2011;In press
32. Hubble JP, Koller WC, Cutler NR, et al. Pramipexole in patients with early Parkinsons disease. Clin Neuropharmacol 1995;18(4):338-47
33. Shannon KM, Bennett JP Jr, Friedman JH. Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinsons disease. The Pramipexole Study Group. Neurology 1997;49(3):724-8 (Pubitemid 27428013)
34. PSG. Safety and efficacy of pramipexole in early Parkinson disease. A randomized dose ranging study. Parkinson Study Group. JAMA 1997;278(2):125-30
35. Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial. JAMA 2000;284(15):1931-8
36. Navan P, Findley LJ, Jeffs JA, et al. Randomized, double-blind, 3-month parallel study of the effects of pramipexole, pergolide, and placebo on parkinsonian tremor. Mov Disord 2003;18:1324-31 (Pubitemid 38263318)
37. Wermuth L. A double-blind, placebo-controlled, randomized, multi-center study of pramipexole in advanced Parkinsons disease. Eur J Neurol 1998;5(3):235-42 (Pubitemid 28256611)
38. Lieberman A, Ranhosky A, Korts D. Clinical evaluation of pramipexole in advanced Parkinsons disease: results of a double-blind, placebo-controlled, parallel-group study. Neurology 1997;49:162-8 (Pubitemid 27328697)
39. Pinter MM, Pogarell O, Oertel WH. Efficacy, safety, and tolerance of the non-ergoline dopamine agonist pramipexole in the treatment of advanced Parkinsons disease: a double blind, placebo controlled, randomised, multicentre study. J Neurol Neurosurg Psychiatry 1999;66(4):436-41 (Pubitemid 29145676)
40. Guttman M. Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinsons disease. International Pramipexole-Bromocriptine Study Group. Neurology 1997;49(4):1060-5 (Pubitemid 27456088)
41. Mizuno Y, Yanagisawa N, Kuno S, et al. Randomized, double-blind study of pramipexole with placebo and bromocriptine in advanced Parkinsons disease. Mov Disord 2003;18(10):1149-56 (Pubitemid 37336939)